THERAPY DOSSIER · th-c0af77f45364

Lippia thymoides crude extracts and dichloromethane and ethyl acetate fractions from leaves and stems

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25892998 ↗2015Mixed findings

Pharmacological Basis for Traditional Use of the Lippia thymoides.

MixedWoundmale and female (acute toxicity assay in mice)crude extract from leaves 1200 mg/kg for the antipyretic as…

Model: Excisional skin wound in rats and baker's yeast-induced fever in young rats, with acute oral toxicity assessment in mice

Crude extracts showed no difference in wound healing versus negative control, but the leaf crude extract at 1200 mg/kg reduced temperature in hyperpyrexic rats with efficacy equal to dipyrone and better than paracetamol. No mortality, behavioural change or adverse effect in the acute toxicity test.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…